Cochlear's share price slumps as it recalls implant on failure risk
This article was originally published in Clinica
Australian hearing implant specialist Cochlear is recalling its Nucleus CI500 range of cochlear implants after seeing an increased failure rate with one of the product models, the Nucleus CI512. In the event of failure, the device safely shuts down without injuring the recipient, according to Cochlear, the number-one firm in the cochlear implant market.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.